Anand Rathi: Stellar Quarter For Aarti Drugs, China Disruption Unleashes Tremendous Growth Opportunity
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Anand Rathi Report
As a prominent partner of pharma companies seeking to diversify supplies from China, Aarti Drugs Ltd.’s Q1 sales grew 34% YoY.
A better product mix and higher realisations on key active pharmaceutical ingredients (prices rose 10-15%) led to a 772 basis point gross-margin expansion.
The Ebitda margin swung to a record 24.6% (a 1,110 basis point expansion). Absolute Ebitda grew 145% to Rs 1.3 billion.
The better operating performance and lower tax rate rocketed adjusted profit after tax 281% to Rs 855 million.
The production-linked Rs 100 billion incentive scheme announced by the Indian government will benefit those like Aarti Drugs.
It has shortlisted a basket of products it plans to manufacture under this scheme. It is also evaluating contract manufacturing of specialty products, earlier manufactured in China.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.